Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
16 - Women and children with myeloproliferative neoplasms – special considerations
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 137 - 151Publisher: Cambridge University PressPrint publication year: 2016
References
Barbui, T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia 2012;26(7):1452–1457.CrossRefGoogle ScholarPubMed
Teofili, L, Giona, F, Martini, M, Cenci, T, Guidi, F, Torti, L, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007;25(9):1048–1053.CrossRefGoogle ScholarPubMed
Hasle, H. Incidence of essential thrombocythaemia in children. Br J Haematol 2000;110(3):751.CrossRefGoogle ScholarPubMed
Dame, C, Sutor, AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005;129(2):165–177.CrossRefGoogle ScholarPubMed
Cario, H, McMullin, MF, Bento, C, Pospisilova, D, Percy, MJ, Hussein, K, et al. Erythrocytosis in children and adolescents – classification, characterization, and consensus recommendations for the diagnostic approach. Pediatr Blood Cancer 2013;60(11):1734–1738.CrossRefGoogle ScholarPubMed
DeLario, MR, Sheehan, AM, Ataya, R, Bertuch, AA, Vega, C, 2nd, Webb, CR, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis – an entity different from adults. Am J Hematol 2012;87(5):461–464.CrossRefGoogle ScholarPubMed
Slone, JS, Smith, MC, Seegmiller, AC, Sidonio, RF, Yang, E. Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process? J Pediatr Hematol Oncol 2013;35(7):559–565.CrossRefGoogle ScholarPubMed
Kucine, N, Chastain, KM, Mahler, MB, Bussel, JB. Primary thrombocytosis in children. Haematologica 2014;99(4):620–628.CrossRefGoogle ScholarPubMed
Subramaniam, N, Mundkur, S, Kini, P, Bhaskaranand, N, Aroor, S. Clinicohematological study of thrombocytosis in children. ISRN Hematol 2014;2014:389257.CrossRefGoogle ScholarPubMed
Kiro, K, Ganjoo, P, Saigal, D, Hansda, U. Incidental thrombocytosis: should it concern the anesthesiologist? J Anaesthesiol Clin Pharmacol 2014;30(2):281–283.Google ScholarPubMed
Reiss, UM, Bensimhon, P, Zimmerman, SA, Ware, RE. Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease. Am J Hematol 2007;82(8):740–743.CrossRefGoogle ScholarPubMed
Prakobkaew, N, Singsanan, S, Fucharoen, G, Surapot, S, Fucharoen, S. Secondary erythrocytosis caused by hemoglobin Tak/(deltabeta)0-thalassemia syndrome. Acta Haematol 2010;124(2):115–119.CrossRefGoogle ScholarPubMed
Naithani, R, Tyagi, S, Choudhry, VP. Secondary myelofibrosis in children. J Pediatr Hematol Oncol 2008;30(3):196–198.CrossRefGoogle ScholarPubMed
Galluzzo, ML, Braier, J, Rosenzweig, SD, Garcia de Davila, MT, Rosso, D. Bone marrow findings at diagnosis in patients with multisystem Langerhans cell histiocytosis. Pediatr Dev Pathol 2010;13(2):101–106.CrossRefGoogle ScholarPubMed
Shah, I, Murthy, A. Bone marrow abnormalities in HIV infected children, report of three cases and review of the literature. J Res Med Sci 2014;19(2):181–183.Google ScholarPubMed
Henry, M, Chitlur, M, Rajpurkar, M, Mastropietro, CW, Poulik, J, Ravindranath, Y. Myelofibrosis, hepatic extramedullary hematopoiesis and ascites associated with vitamin D deficiency in early infancy. J Pediatr Hematol Oncol 2014;36(4):319–321.CrossRefGoogle ScholarPubMed
Albayrak, C, Albayrak, D, Kilinc, AA, Kara, C. Myelofibrosis associated with rickets in a child with Down syndrome. Pediatr Blood Cancer 2012;58(4):647–648.CrossRefGoogle Scholar
Cooperberg, AA, Singer, OP. Reversible myelofibrosis due to vitamin D deficiency rickets. Can Med Assoc J 1966;94(8):392–395.Google ScholarPubMed
Hong, WJ, Gotlib, J. Hereditary erythrocytosis, thrombocytosis and neutrophilia. Best Pract Res Clin Haematol 2014;27(2):95–106.CrossRefGoogle ScholarPubMed
Greer, JP, Foerster, J, Lukens, J, Rodgers, G, Paraskevas, F, Glader, B (eds.) Wintrobe’s Clinical Hematology, 11th edn. Philadelphia: Lippincott Williams & Wilkins; 2004.Google Scholar
Teofili, L, Larocca, LM. Advances in understanding the pathogenesis of familial thrombocythaemia. Br J Haematol 2011;152(6):701–712.CrossRefGoogle ScholarPubMed
Liu, K, Martini, M, Rocca, B, Amos, CI, Teofili, L, Giona, F, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica 2009;94(10):1368–1374.CrossRefGoogle ScholarPubMed
Kikuchi, M, Tayama, T, Hayakawa, H, Takahashi, I, Hoshino, H, Ohsaka, A. Familial thrombocytosis. Br J Haematol 1995;89(4):900–902.CrossRefGoogle ScholarPubMed
Teofili, L, Giona, F, Torti, L, Cenci, T, Ricerca, BM, Rumi, C, et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 2010;95(1):65–70.CrossRefGoogle ScholarPubMed
Zhang, B, Ng, D, Jones, C, Oh, ST, Nolan, GP, Salehi, S, et al. A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood 2011;118(26):6988–6990.CrossRefGoogle Scholar
de la Chapelle, A, Traskelin, AL, Juvonen, E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 1993;90(10):4495–4499.CrossRefGoogle ScholarPubMed
Prchal, JT, Semenza, GL, Prchal, J, Sokol, L. Familial polycythemia. Science 1995;268(5219):1831–1832.CrossRefGoogle ScholarPubMed
Sokol, L, Luhovy, M, Guan, Y, Prchal, JF, Semenza, GL, Prchal, JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995;86(1):15–22.CrossRefGoogle ScholarPubMed
Bento, C, Percy, MJ, Gardie, B, Maia, TM, van Wijk, R, Perrotta, S, et al. Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat 2014;35(1):15–26.CrossRefGoogle ScholarPubMed
Bento, C, Almeida, H, Maia, TM, Relvas, L, Oliveira, AC, Rossi, C, et al. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (where is/are the missing gene(s)?). Eur J Haematol 2013;91(4):361–368.CrossRefGoogle ScholarPubMed
Van Maerken, T, Hunninck, K, Callewaert, L, Benoit, Y, Laureys, G, Verlooy, J. Familial and congenital polycythemias: a diagnostic approach. J Pediatr Hematol Oncol 2004;26(7):407–416.CrossRefGoogle ScholarPubMed
Pardanani, AD, Levine, RL, Lasho, T, Pikman, Y, Mesa, RA, Wadleigh, M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472–3476.CrossRefGoogle ScholarPubMed
Pikman, Y, Lee, BH, Mercher, T, McDowell, E, Ebert, BL, Gozo, M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270.CrossRefGoogle ScholarPubMed
Beer, PA, Campbell, PJ, Scott, LM, Bench, AJ, Erber, WN, Bareford, D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112(1):141–149.CrossRefGoogle ScholarPubMed
Harrison, CN, Bareford, D, Butt, N, Campbell, P, Conneally, E, Drummond, M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149(3):352–375.CrossRefGoogle ScholarPubMed
Klampfl, T, Gisslinger, H, Harutyunyan, AS, Nivarthi, H, Rumi, E, Milosevic, JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379–2390.CrossRefGoogle ScholarPubMed
Kucine, N, Chastain, KM, Mahler, MB, Bussel, JB. Primary thrombocytosis in children. Haematologica 2014;99(4):620–628.CrossRefGoogle ScholarPubMed
Randi, ML, Putti, MC, Scapin, M, Pacquola, E, Tucci, F, Micalizzi, C, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006;108(10):3600–3602.CrossRefGoogle ScholarPubMed
Nakatani, T, Imamura, T, Ishida, H, Wakaizumi, K, Yamamoto, T, Otabe, O, et al. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Pediatr Blood Cancer 2008;51(6):802–805.CrossRefGoogle ScholarPubMed
Teofili, L, Foa, R, Giona, F, Larocca, LM. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients? Haematologica 2008;93(2):169–172.CrossRefGoogle ScholarPubMed
Nangalia, J, Massie, CE, Baxter, EJ, Nice, FL, Gundem, G, Wedge, DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369(25):2391–2405.CrossRefGoogle ScholarPubMed
Klampfl, T, Gisslinger, H, Harutyunyan, AS, Nivarthi, H, Rumi, E, Milosevic, JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379–2390.CrossRefGoogle ScholarPubMed
Langabeer, SE, Haslam, K, McMahon, C. CALR mutations are rare in childhood essential thrombocythemia. Pediatr Blood Cancer 2014;61(8):1523.CrossRefGoogle ScholarPubMed
Giona, F, Teofili, L, Capodimonti, S, Laurino, M, Martini, M, Marzella, D, et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood 2014;123(23):3677–3679.CrossRefGoogle ScholarPubMed
Cario, H, McMullin, MF, Pahl, HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol 2009;88(8):713–719.CrossRefGoogle ScholarPubMed
Giona, F, Teofili, L, Moleti, ML, Martini, M, Palumbo, G, Amendola, A, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 2012;119(10):2219–2227.CrossRefGoogle ScholarPubMed
Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29(6):761–770.CrossRefGoogle ScholarPubMed
Barbui, T, Finazzi, MC, Finazzi, G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 2012;26(5):205–211.CrossRefGoogle ScholarPubMed
Dror, Y, Blanchette, VS. Essential thrombocythaemia in children. Br J Haematol 1999;107(4):691–698.CrossRefGoogle ScholarPubMed
Barbui, T, Finazzi, G. Special issues in myeloproliferative neoplasms. Curr Hematol Malig Rep 2011;6(1):28–35.CrossRefGoogle ScholarPubMed
Marchioli, R, Finazzi, G, Specchia, G, Masciulli, A, Mennitto, MR, Barbui, T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis 2011;2011:794240.CrossRefGoogle ScholarPubMed
Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368(1):22–33.CrossRefGoogle ScholarPubMed
Frezzato, M, Ruggeri, M, Castaman, G, Rodeghiero, F. Polycythemia vera and essential thrombocythemia in young patients. Haematologica 1993;78(6 Suppl 2):11–17.Google ScholarPubMed
Najean, Y, Mugnier, P, Dresch, C, Rain, JD. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol 1987;67(3):285–291.CrossRefGoogle ScholarPubMed
Cario, H, Schwarz, K, Herter, JM, Komrska, V, McMullin, MF, Minkov, M, et al. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br J Haematol 2008;142(4):622–626.CrossRefGoogle ScholarPubMed
Goldstein, G, Maor, J, Kleinbaum, Y, Palumbo, M, Sidi, Y, Salomon, O. Budd–Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment. Blood Coagul Fibrinolysis 2013;24(8):848–853.CrossRefGoogle ScholarPubMed
Passamonti, F, Malabarba, L, Orlandi, E, Barate, C, Canevari, A, Brusamolino, E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003;88(1):13–18.Google Scholar
Ruggeri, M, Finotto, S, Fortuna, S, Rodeghiero, F. Treatment outcome in a cohort of young patients with polycythemia vera. Intern Emerg Med 2010;5(5):411–413.CrossRefGoogle Scholar
Finazzi, G, Barbui, T. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. Pathol Biol (Paris) 2001;49(2):167–169.CrossRefGoogle ScholarPubMed
Bjorkholm, M, Derolf, AR, Hultcrantz, M, Kristinsson, SY, Ekstrand, C, Goldin, LR, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29(17):2410–2415.CrossRefGoogle ScholarPubMed
Sterkers, Y, Preudhomme, C, Lai, JL, Demory, JL, Caulier, MT, Wattel, E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91(2):616–622.CrossRefGoogle ScholarPubMed
Finazzi, G, Ruggeri, M, Rodeghiero, F, Barbui, T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003;101(9):3749.CrossRefGoogle Scholar
Finazzi, G, Caruso, V, Marchioli, R, Capnist, G, Chisesi, T, Finelli, C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105(7):2664–2670.CrossRefGoogle ScholarPubMed
Stein, BL, Tiu, RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res 2013;33(4):145–153.CrossRefGoogle ScholarPubMed
Ianotto, JC, Boyer-Perrard, F, Gyan, E, Laribi, K, Cony-Makhoul, P, Demory, JL, et al. Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013;162(6):783–791.CrossRefGoogle ScholarPubMed
Jabbour, E, Kantarjian, H, Cortes, J, Thomas, D, Garcia-Manero, G, Ferrajoli, A, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007;110(9):2012–2018.CrossRefGoogle ScholarPubMed
Samuelsson, J, Hasselbalch, H, Bruserud, O, Temerinac, S, Brandberg, Y, Merup, M, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006;106(11):2397–2405.CrossRefGoogle ScholarPubMed
Silver, RT. Are all interferons the same for therapy in polycythemia vera? Clin Lymphoma Myeloma Leuk 2013;13(Suppl 2):S305–6.CrossRefGoogle ScholarPubMed
Stauffer Larsen, T, Iversen, KF, Hansen, E, Mathiasen, AB, Marcher, C, Frederiksen, M, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013;37(9):1041–1045.CrossRefGoogle Scholar
Yazdani Brojeni, P, Matok, I, Garcia Bournissen, F, Koren, G. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 2012;33(3):265–268.CrossRefGoogle ScholarPubMed
Griesshammer, M, Bergmann, L, Pearson, T. Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clin Haematol 1998;11(4):859–874.CrossRefGoogle ScholarPubMed
Bangerter, M, Guthner, C, Beneke, H, Hildebrand, A, Grunewald, M, Griesshammer, M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol 2000;65(3):165–169.CrossRefGoogle ScholarPubMed
Lanzkron, S, Strouse, JJ, Wilson, R, Beach, MC, Haywood, C, Park, H, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008;148(12):939–955.CrossRefGoogle ScholarPubMed
Domm, J, Calder, C, Manes, B, Crossno, C, Correa, H, Frangoul, H. Unrelated stem cell transplant for infantile idiopathic myelofibrosis. Pediatr Blood Cancer 2009;52(7):893–895.CrossRefGoogle ScholarPubMed
Sekhar, M, Prentice, HG, Popat, U, Anderson, D, Janmohammed, R, Roberts, I, et al. Idiopathic myelofibrosis in children. Br J Haematol 1996;93(2):394–397.CrossRefGoogle ScholarPubMed
Reilly, JT, McMullin, MF, Beer, PA, Butt, N, Conneally, E, Duncombe, A, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012;158(4):453–471.CrossRefGoogle ScholarPubMed
Loh, ML, Tasian, SK, Rabin, KR, Brown, P, Magoon, D, Reid, JM, et al. A phase I dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children’s Oncology Group phase I consortium study (ADVL1011). Pediatr Blood Cancer 2015;62(10): 1717–1724.CrossRefGoogle ScholarPubMed
Hoffman, R (ed.) Hematology: Basic Principles and Practice, 6th edn. Philadelphia; PA: Saunders/Elsevier; 2013.Google Scholar
Titmarsh, GJ, Duncombe, AS, McMullin, MF, O’Rorke, M, Mesa, R, De Vocht, F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 2014;89(6):581–587.CrossRefGoogle ScholarPubMed
Moulard, O, Mehta, J, Fryzek, J, Olivares, R, Iqbal, U, Mesa, RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 2014;92(4):289–297.CrossRefGoogle ScholarPubMed
Stein, BL, Rademaker, A, Spivak, JL, Moliterno, AR. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis 2011;2011:874146.CrossRefGoogle ScholarPubMed
Stein, BL, Williams, DM, Wang, NY, Rogers, O, Isaacs, MA, Pemmaraju, N, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 2010;95(7):1090–1097.CrossRefGoogle ScholarPubMed
Landolfi, R, Di Gennaro, L, Nicolazzi, MA, Giarretta, I, Marfisi, R, Marchioli, R. Polycythemia vera: gender-related phenotypic differences. Intern Emerg Med 2012;7(6):509–515.CrossRefGoogle ScholarPubMed
Gangat, N, Wolanskyj, AP, Tefferi, A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006;77(4):327–333.CrossRefGoogle ScholarPubMed
Dentali, F, Ageno, W, Rumi, E, Casetti, I, Poli, D, Scoditti, U, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res 2014;134(1):41–43.CrossRefGoogle ScholarPubMed
Passamonti, SM, Biguzzi, E, Cazzola, M, Franchi, F, Gianniello, F, Bucciarelli, P, et al. The JAK2 V617F mutation in patients with cerebral venous thrombosis. J Thromb Haemost 2012;10(6):998–1003.CrossRefGoogle ScholarPubMed
Smalberg, JH, Arends, LR, Valla, DC, Kiladjian, JJ, Janssen, HL, Leebeek, FW. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012;120(25):4921–4928.CrossRefGoogle ScholarPubMed
Gangat, N, Wolanskyj, AP, Schwager, SM, Mesa, RA, Tefferi, A. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 2006;106(11):2406–2411.CrossRefGoogle ScholarPubMed
Leal, AD, Thompson, CA, Wang, AH, Vierkant, RA, Habermann, TM, Ross, JA, et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women’s Health Study cohort. Int J Cancer 2014;134(7):1741–1750.CrossRefGoogle ScholarPubMed
Abelsson, J, Andreasson, B, Samuelsson, J, Hultcrantz, M, Ejerblad, E, Johansson, B, et al. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma 2013;54(10):2226–2230.CrossRefGoogle ScholarPubMed
Scherber, RM, Geyer, HL, Mesa, RA. Quality of life in MPN comes of age as a therapeutic target. Curr Hematol Malig Rep 2014;9(4):324–330.CrossRefGoogle ScholarPubMed